Central Nervous System Therapeutics Market Report 2026

The central nervous system therapeutics market size has grown strongly in recent years. It will grow from $134.99 billion in 2025 to $147.29 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing burden of depression and epilepsy, growing aging population, limited treatment options for degenerative disorders, rising hospitalization rates for cns conditions, expansion of hospital and clinic infrastructure.

The central nervous system therapeutics market size is expected to see strong growth in the next few years. It will grow to $206.68 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to development of novel neuroprotective agents, growth in biologics and gene-based therapies, increasing investment in neuroscience research, rising adoption of personalized medicine, expanding access to cns treatments in emerging markets. Major trends in the forecast period include rising prevalence of neurological and mental health disorders, growing adoption of combination therapies for cns diseases, increasing focus on long-term disease management and symptom control, expansion of homecare-based cns treatment solutions, improved drug formulations with better blood-brain barrier penetration.

The increasing prevalence of mental health disorders is expected to drive the growth of the central nervous system (CNS) therapeutics market in the coming years. Mental health disorders encompass a broad range of conditions that affect a person’s thinking, emotions, behavior, or mood, including depression, anxiety disorders, schizophrenia, and bipolar disorder. The rising prevalence of these disorders is largely attributed to greater exposure to chronic stress, which can disrupt emotional regulation, weaken coping mechanisms, and contribute to conditions such as anxiety, depression, and burnout. CNS therapeutics address mental health disorders by targeting brain chemicals and neural pathways that regulate mood, behavior, and cognition. For instance, in December 2025, according to a report published by Bristol City Council, a UK-based local government authority, 66,815 patients aged 18 and above were recorded on GP practice depression registers in Bristol during 2022-23, representing a 6% increase from 2021-22. Therefore, the rising prevalence of mental health disorders is driving the growth of the CNS therapeutics market.

Major companies operating in the CNS therapeutics market are focusing on innovative solutions such as capsid engineering to enhance targeted gene delivery, improve therapeutic efficacy, and optimize blood-brain barrier penetration for neurological disorder treatments. Capsid engineering involves modifying and optimizing the protein shell (capsid) of viral vectors, typically adeno-associated viruses (AAVs), used in gene therapy. For example, in May 2025, Coave Therapeutics S.A., a France-based biotechnology company, launched coAAV CSF-01, a novel AAV for CNS delivery using their proprietary ALIGATER platform. The vector demonstrated significantly enhanced transduction efficiency and safety compared to AAV9. Delivered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Equivalent expression levels to AAV9 were achieved at just one-fifth of the dose, highlighting its superior potency. The vector also showed markedly reduced off-target expression in peripheral organs such as the liver while maintaining a favorable safety profile, including preserved peripheral nerve integrity, underscoring its potential to improve CNS gene therapy outcomes with higher precision and lower systemic risk.

In June 2025, Supernus Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Sage Therapeutics Inc. for an undisclosed amount. This acquisition allows Supernus to expand its neuroscience portfolio, strengthen its position in the CNS market, and accelerate the development of innovative treatments for depression and other mood disorders. Sage Therapeutics Inc. is a US-based biopharmaceutical company specializing in CNS therapeutics.

Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.

North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the central nervous system therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the central nervous system therapeutics market by increasing the cost of imported active pharmaceutical ingredients, biologics, and specialized manufacturing equipment, leading to higher production expenses and pricing pressures. Drug classes such as biologics and advanced neurotherapies are most affected, particularly in regions like North America and Europe that depend on global supply chains. These challenges have caused temporary delays in product availability. However, tariffs have also encouraged domestic manufacturing, regional supply chain diversification, and increased investment in local R&D for CNS therapeutics.

The central nervous system therapeutics market research report is one of a series of new reports that provides central nervous system therapeutics market statistics, including central nervous system therapeutics industry global market size, regional shares, competitors with a central nervous system therapeutics market share, detailed central nervous system therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system therapeutics industry. This central nervous system therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Central nervous system therapeutics are drugs and treatment approaches developed to manage and treat disorders of the brain and spinal cord. These include conditions such as depression, epilepsy, Parkinson’s disease, and multiple sclerosis. Their purpose is to restore neurological function, relieve symptoms, and improve patients’ quality of life. They encompass pharmaceuticals, biologics, and advanced neurotechnological interventions.

The main drug classes in central nervous system therapeutics include anesthetics, anticonvulsants, antiemetics, central nervous system (CNS) stimulants, pain relievers, and others. Anesthetics are medications that block pain or induce unconsciousness during medical procedures. These therapies are applied across various disease areas, including neurovascular disorders, mental health conditions, degenerative diseases, genetic disorders, substance abuse, autoimmune and inflammatory diseases, CNS trauma, infectious diseases, CNS cancers, and others. They are distributed through channels such as hospital pharmacies, retail pharmacies, and others, and are used in applications including hospitals, clinics, homecare, and other care settings.

The central nervous system therapeutics market consists of sales of sodium channel blockers, amphetamines, and neuroprotective agents. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.